MX9203629A - Composiciones de anticuerpos monoclonales para el tratamiento profilactico o terapeutico de infecciones bacterianas debidas a estreptococos del grupo b. - Google Patents

Composiciones de anticuerpos monoclonales para el tratamiento profilactico o terapeutico de infecciones bacterianas debidas a estreptococos del grupo b.

Info

Publication number
MX9203629A
MX9203629A MX9203629A MX9203629A MX9203629A MX 9203629 A MX9203629 A MX 9203629A MX 9203629 A MX9203629 A MX 9203629A MX 9203629 A MX9203629 A MX 9203629A MX 9203629 A MX9203629 A MX 9203629A
Authority
MX
Mexico
Prior art keywords
streptococces
prophylactic
group
monoclonal antibodies
therapeutic treatment
Prior art date
Application number
MX9203629A
Other languages
English (en)
Spanish (es)
Inventor
Howard V Raff
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX9203629A publication Critical patent/MX9203629A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX9203629A 1986-02-07 1992-06-26 Composiciones de anticuerpos monoclonales para el tratamiento profilactico o terapeutico de infecciones bacterianas debidas a estreptococos del grupo b. MX9203629A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82800586A 1986-02-07 1986-02-07
US94449586A 1986-12-19 1986-12-19

Publications (1)

Publication Number Publication Date
MX9203629A true MX9203629A (es) 1992-07-01

Family

ID=27125154

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9203629A MX9203629A (es) 1986-02-07 1992-06-26 Composiciones de anticuerpos monoclonales para el tratamiento profilactico o terapeutico de infecciones bacterianas debidas a estreptococos del grupo b.

Country Status (28)

Country Link
US (2) US5717071A (OSRAM)
JP (1) JP2645343B2 (OSRAM)
KR (1) KR870007697A (OSRAM)
CN (1) CN87102167A (OSRAM)
AT (1) AT398781B (OSRAM)
BE (1) BE1000967A5 (OSRAM)
CA (1) CA1339013C (OSRAM)
CH (1) CH672072A5 (OSRAM)
DE (1) DE3703711A1 (OSRAM)
DK (1) DK63187A (OSRAM)
ES (1) ES2009140A6 (OSRAM)
FI (1) FI94489C (OSRAM)
FR (1) FR2595946B1 (OSRAM)
GB (1) GB2186592B (OSRAM)
GR (1) GR870194B (OSRAM)
HK (1) HK21795A (OSRAM)
HU (1) HU203583B (OSRAM)
IE (1) IE59627B1 (OSRAM)
IL (1) IL81370A (OSRAM)
IT (1) IT1207589B (OSRAM)
LU (1) LU86761A1 (OSRAM)
MX (1) MX9203629A (OSRAM)
NL (1) NL8700286A (OSRAM)
NO (1) NO176924C (OSRAM)
NZ (2) NZ219187A (OSRAM)
OA (1) OA08477A (OSRAM)
PT (1) PT84258B (OSRAM)
SE (1) SE468747B (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256713A3 (en) * 1986-08-06 1989-02-15 Merck & Co. Inc. Therapeutic human antipseudomonas aeruginosa antibodies
CA1341375C (en) * 1988-10-12 2002-07-09 Baxter International Inc. Compositions and methods for the treatment and prevention of gram-negative bacterial infections
DE3925161A1 (de) * 1989-03-15 1990-09-27 Boehringer Mannheim Gmbh Monoklonale, gegen eca gerichtete antikoerper und ihre verwendung
JPH0329196A (ja) * 1989-05-09 1991-02-07 Advanced Micro Devicds Inc センス増幅器
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
US6315999B1 (en) 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
EP1027896A1 (en) * 1992-03-19 2000-08-16 Henry M. Jackson Foundation For The Advancement Of Military Medicine Broadly reactive opsonic antibodies that react with common staphyloccoccal antigens
WO1994015640A1 (en) * 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
ATE474849T1 (de) * 1998-04-14 2010-08-15 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
ES2397488T3 (es) * 2007-07-23 2013-03-07 Sanofi Pasteur Limited Polipéptidos inmunógenos y anticuerpos monoclonales
EP2411413B1 (en) * 2009-03-23 2016-05-11 Quark Pharmaceuticals, Inc. Compounds compositions and methods of treating cancer and fibrotic diseases
KR20140009281A (ko) 2010-12-03 2014-01-22 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 스트렙토코커스 뉴모니애에 대한 면역화를 위한 조성물
ES2981535T3 (es) * 2015-11-10 2024-10-09 Visterra Inc Conjugados de molécula de anticuerpo-fármaco que se unen específicamente al lipopolisacárido y usos de los mismos
CN110431150A (zh) 2017-01-18 2019-11-08 威特拉公司 抗体分子-药物偶联物及其用途
CA3178465A1 (en) 2020-04-03 2021-10-07 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
CA1262238A (en) * 1982-09-30 1989-10-10 Richard Insel Human monoclonal antibodies against bacterial toxins
US4587121A (en) * 1983-06-14 1986-05-06 Miles Laboratories, Inc. High titer Pseudomonas immune serum globulin
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
US4834975A (en) * 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
DE3426903A1 (de) * 1984-07-20 1986-01-23 Biotest Pharma GmbH, 6000 Frankfurt Eine immunglobulinpraeparation in kombination mit einer anderen pharmakologisch wirksamen praeparation zur verwendung bei der behandlung von krankheiten
US4675287A (en) * 1984-07-26 1987-06-23 Scripps Clinic And Research Foundation Monoclonal antibody directed to human ganglioside GD2
US4677070A (en) * 1985-04-26 1987-06-30 Cetus Corporation Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use
US4772464A (en) * 1985-08-01 1988-09-20 Miles Laboratories, Inc. Protective antibodies to serotypic determinants of flagellar antigens
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US4777136A (en) * 1985-09-27 1988-10-11 The Regents Of The University Of California Monoclonal antibody reactive with Pseudomonas Aeruginosa
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
US4970070A (en) * 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus

Also Published As

Publication number Publication date
IE59627B1 (en) 1994-03-09
NO870476D0 (no) 1987-02-06
DE3703711C2 (OSRAM) 1993-06-24
SE8700467L (sv) 1987-08-08
IT1207589B (it) 1989-05-25
FR2595946B1 (fr) 1991-10-04
IT8719292A0 (it) 1987-02-06
SE468747B (sv) 1993-03-15
NZ219187A (en) 1990-12-21
NO870476L (no) 1987-08-10
HK21795A (en) 1995-02-24
HUT46062A (en) 1988-09-28
CH672072A5 (OSRAM) 1989-10-31
IE870320L (en) 1987-08-07
AT398781B (de) 1995-01-25
CN87102167A (zh) 1988-02-03
SE8700467D0 (sv) 1987-02-06
US5717071A (en) 1998-02-10
NZ233920A (en) 1990-12-21
ATA26287A (de) 1994-06-15
DE3703711A1 (de) 1987-09-24
GB8702689D0 (en) 1987-03-11
ES2009140A6 (es) 1989-09-01
FI94489B (fi) 1995-06-15
IL81370A (en) 1991-06-30
BE1000967A5 (fr) 1989-05-30
GR870194B (en) 1987-06-10
GB2186592A (en) 1987-08-19
US5837541A (en) 1998-11-17
FI870502A0 (fi) 1987-02-06
DK63187D0 (da) 1987-02-06
JPS62270535A (ja) 1987-11-24
FI870502L (fi) 1987-08-08
NO176924C (no) 1995-06-21
HU203583B (en) 1991-08-28
GB2186592B (en) 1990-08-01
JP2645343B2 (ja) 1997-08-25
IL81370A0 (en) 1987-08-31
CA1339013C (en) 1997-03-25
DK63187A (da) 1987-08-08
LU86761A1 (fr) 1987-09-15
OA08477A (fr) 1988-07-29
KR870007697A (ko) 1987-09-21
PT84258B (pt) 1989-09-14
NL8700286A (nl) 1987-09-01
NO176924B (no) 1995-03-13
PT84258A (en) 1987-03-01
FR2595946A1 (fr) 1987-09-25
FI94489C (fi) 1995-09-25

Similar Documents

Publication Publication Date Title
MX9203629A (es) Composiciones de anticuerpos monoclonales para el tratamiento profilactico o terapeutico de infecciones bacterianas debidas a estreptococos del grupo b.
NO165877C (no) Ikke-vandig hydroformyleringsprosess for fremstilling av olefiner.
NO834146L (no) Fremgangsmaate for fremstilling av epimert azahomoerytromycin a
MA22842A1 (fr) Procede de preparation de compositions de vaccin.
FI873113L (fi) Tvaettmedelskomposition.
IT7829622A0 (it) Procedimento per la purificazione di silicio.
AR193590A1 (es) Procedimiento para la preparacion de 2,2'-metilendifenoles sustituidos
NO871715L (no) Fremgangsmaate for fremstilling av alfa-olefinpolymer.
NO160444C (no) Analogifremgangsmaate for fremstilling av nye, terapeutiskaktive imidazo-pyrazolo-pyrimidiner.
ES2013631B3 (es) Metodo para el tratamiento de tejidos.
BE795950A (fr) Procede de preparation d'amidosilanes
IT8119673A0 (it) Composizioni farmaceutiche per il trattamento di osteopatie.
DK550586A (da) Laegemiddel til behandling af neuropsykiatriske tilstande, saasom demens
FR2664274B1 (fr) Procede de preparation de sulfates cycliques.
ES518181A0 (es) Procedimiento para la preparacion de inmunoglobulina administrable por via intravenosa.
FI831192A7 (fi) Menetelmä substituoitujen 2- aminobentsimidatsolien valmistamiseksi.
FI874414A0 (fi) Kontrollerat frigoerande farmaceutiska kompositioner.
IT7924246A0 (it) Procedimento per la purificazione di resorcina grezza.
FI933755A7 (fi) Menetelmä trans-piperidiini-2,5-dikarboksylaattien valmistamiseksi
IT7926493A0 (it) Impianto rotante per il trattamento di recipienti.
FI872459A7 (fi) Farmaseuttinen valmiste bakteeri-infektioiden hoitoon.
ES2019594B3 (es) Metodo de tamponado del ph.
IT8319024A0 (it) Composizione medicinale per il trattamento di certe neurovirosi.
BE790056A (fr) Procede de preparation de 1, 1'-dianthraquinonyles
IT8321573A0 (it) Procedimento per la preparazione del meta-clorobenzotrifluoruro.